Patient-specific dendritic-cell vaccines for metastatic melanoma

被引：29

作者：

Dillman, Robert O. ^{[1
]}

Selvan, Senthamil R. ^{[1
]}

Schiltz, Patric M. ^{[1
]}

机构：

[1] Hoag Canc Ctr, Newport Beach, CA 92658 USA

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 2006年 / 355卷 / 11期

关键词：

D O I：

10.1056/NEJMc061667

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1179 / 1181

页数：3

共 3 条

[1] Phase I/II trial of melanoma patient-speciric vaccine of proliferating autologous tumor cells, dendritic cells, and GM-CSF: Planned interim analysis [J].

Dillman, R ;

Selvan, S ;

Schiltz, P ;

Peterson, C ;

Allen, K ;

DePriest, C ;

McClay, E ;

Barth, N ;

Sheehy, P ;

de Leon, C ;

Beutel, L .

CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2004, 19 (05) :658-665

[2] ESTABLISHING IN-VITRO CULTURES OF AUTOLOGOUS TUMOR-CELLS FOR USE IN ACTIVE SPECIFIC IMMUNOTHERAPY [J].

DILLMAN, RO ;

NAYAK, SK ;

BEUTEL, L .

JOURNAL OF IMMUNOTHERAPY, 1993, 14 (01) :65-69

[3] Short-term autologous tumor cell lines for the active specific immunotherapy of patients with metastatic melanoma [J].

Dillman, RO ;

DeLeon, C ;

Beutel, LD ;

Barth, NM ;

Schwartzberg, LS ;

Spitler, LE ;

Garfield, DH ;

O'Connor, AA ;

Nayak, SK .

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2001, 39 (1-2) :115-123

← 1 →